VYNE Therapeutics Inc VYNE Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$28.56 up $3.11, 12.22% at close Jul 27
Last close · Previous close $25.45
VYNE split 1-for-50 on ; earlier prices are adjusted for it.
- Market cap
- $19.03MAt the Jul 27 close
- P/E ratio
- PausedOn last 12 months’ EPS
See the note under the price. - Diluted EPS
- PausedLast 12 months
See the note under the price. - Dividend yield
- NoneLast 12 months
Price chart
$28.56Past month
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$25.45Jul 24
- Volume93.25KJul 27 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume76.16KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $23.37 to $28.56; now $28.56
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Jul 27 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
There isn’t enough price history yet to measure returns.
There isn’t enough price history yet to measure returns.
All-time high
$28.56
Closing high on .
Split-adjusted daily closes since Jul 24, 2026.
Stock splits
1
1-for-50 on . Share counts adjust after each split.
Valuation
The Jul 27 close compared with the last 12 months of reported results (the four quarters to Mar 31, 2026). Tap a metric to see how it’s calculated. Per-share results and the measures based on them are paused. See the note under the price.
Price-to-earnings (P/E)
Paused
Other valuation measures
- 41.9×Last 12 months’ revenue
Market value divided by revenue over the last 12 months. Useful when earnings are small or negative.
P/S = Market cap ÷ Revenue (last 12 months)Price-to-sales ratio - Price-to-bookPausedBook value as of Mar 31, 2026
See the note under the price. - PEG ratioPausedLast 12 months’ EPS growth
See the note under the price. - −135.25%Last 12 months’ free cash flow
Free cash flow over the last 12 months as a share of the company’s market value: the cash the business generated for each dollar of stock.
FCF yield = Free cash flow (last 12 months) ÷ Market capFree cash flow - −$5.89MAt the Jul 27 close
What it would cost to buy the whole business: the market cap at the Jul 27 close, plus debt, minus cash and short-term investments from the Mar 31, 2026 balance sheet.
EV = Market cap + Debt − Cash and short-term investmentsEV/EBITDA explained
Build your own VYNE DCF in Excel. Value VYNE Therapeutics with your own growth and margin assumptions.Browse DCF models Free DCF calculator
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q1 FY26, the quarter ended Mar 31, 2026. “Last 12 months” means the four quarters from Apr 1, 2025 to Mar 31, 2026, and balance-sheet figures are as of Mar 31, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $454.00Kdown 25.0%
- Net income
- −$21.46M
- Diluted EPS
- PausedSee the note under the price.
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q2 FY24 (Jun 30, 2024) | $198.00K | −$9.41M | Paused See the note under the price. |
| Q3 FY24 (Sep 30, 2024) | $121.00K | −$12.16M | Paused See the note under the price. |
| Q4 FY24 (Dec 31, 2024) | $84.00K | −$12.02M | Paused See the note under the price. |
| Q1 FY25 (Mar 31, 2025) | $202.00K | −$8.61M | Paused See the note under the price. |
| Q2 FY25 (Jun 30, 2025) | $69.00K | −$5.76M | Paused See the note under the price. |
| Q3 FY25 (Sep 30, 2025) | $169.00K | −$7.28M | Paused See the note under the price. |
| Q4 FY25 (Dec 31, 2025) | $130.00K | −$4.84M | Paused See the note under the price. |
| Q1 FY26 (Mar 31, 2026) | $86.00K | −$3.59M | Paused See the note under the price. |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $931.00K | −$73.33M | Paused See the note under the price. |
| FY22 (Dec 31, 2022) | $477.00K | −$23.21M | Paused See the note under the price. |
| FY23 (Dec 31, 2023) | $424.00K | −$28.45M | Paused See the note under the price. |
| FY24 (Dec 31, 2024) | $501.00K | −$39.83M | Paused See the note under the price. |
| FY25 (Dec 31, 2025) | $570.00K | −$26.48M | Paused See the note under the price. |
Margins
- Gross 100.0%
- Operating −5,367.6%
- Net −4,726.2%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$25.74MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$25.74MLast 12 months
- Capital spending$0.00Last 12 months
- −5,670.5%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $0.00Last 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $24.93MAs of Mar 31, 2026
Cash plus short- and long-term marketable securities on the Mar 31, 2026 balance sheet.
- Total debt$0.00As of Mar 31, 2026
- Net cash$24.93MAs of Mar 31, 2026
- Book value per sharePausedAs of Mar 31, 2026
See the note under the price. - 20.86As of Mar 31, 2026
Current assets divided by current liabilities on the Mar 31, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.00As of Mar 31, 2026
Total debt divided by shareholders’ equity on the Mar 31, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 4 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✗Net income was positive: not passed
- ✗Operating cash flow was positive: not passed
- ✓Return on assets improved: passed
- ✗Operating cash flow exceeded net income: not passed
- ✓Long-term debt fell relative to assets: passed
- ✓Current ratio improved: passed
- ✗Share count didn’t rise: not passed
- ✗Gross margin improved: not passed
- ✓Asset turnover (revenue ÷ assets) improved: passed
- −69.6%Last 12 months
Over the last 12 months, VYNE Therapeutics lost money: its net loss was 69.6% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −62.7%Last 12 months
Over the last 12 months, VYNE Therapeutics’s net loss was 62.7% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About VYNE Therapeutics Inc
VYNE Therapeutics Inc
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- New Jersey, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
VYNE news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
VYNE stock FAQ
What is VYNE stock’s price today?
VYNE Therapeutics (VYNE) traded at $28.56 at the close on , up $3.11 (12.22%) from the previous close of $25.45. Over the past 52 weeks it has traded between $23.37 and $28.56.
What is VYNE Therapeutics’s market cap?
VYNE Therapeutics’s market capitalization is about $19.0 million. That’s Tiingo’s daily market cap for , at that day’s closing price of $28.56 (how market cap works).
How much revenue does VYNE Therapeutics make?
VYNE Therapeutics reported $454.0 thousand of revenue over the four quarters to , down 25.0% from the twelve months before. In its latest quarter (Q1 FY26, ended ) revenue was $86.0 thousand, down 57.4% from a year earlier.
Is VYNE Therapeutics profitable?
Not over the four quarters to . VYNE Therapeutics reported a net loss of $21.5 million across those four quarters on $454.0 thousand of revenue.
Does VYNE pay a dividend?
VYNE Therapeutics hasn’t paid a dividend in the last twelve months.
What is VYNE’s 52-week high and low?
Over the past 52 weeks VYNE has traded as low as $23.37 and as high as $28.56. At $28.56 at the close on , it is 0.0% below that high and 22.2% above the low.
What is VYNE’s all-time high?
VYNE’s highest closing price was $28.56 on , adjusted for stock splits.
Has VYNE stock ever split?
Yes, once: 1-for-50 on .
What sector and industry is VYNE Therapeutics in?
VYNE Therapeutics is in the Healthcare sector and the Biotechnology industry, and is headquartered in New Jersey, USA.
What exchange does VYNE trade on?
VYNE Therapeutics trades on the Nasdaq under the ticker symbol VYNE. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.